Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATO + ATRA vs AIDA chemotherapy for newly diagnosed non–high-risk acute promyelocytic leukemia
2006-006188-22Phase 3Completed
- Sponsor
- GIMEMA
- Start
- Jul 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of arsenic trioxide, tretinoin, idarubicin, mitoxantrone, mercaptopurine and 1 more in Acute promyelocytic leukaemia (APL) (2 arms), sponsored by GIMEMA. Primary endpoint: Event-free survival probability at 2 years. Started Jul 2007; status: completed.
02
Drugs
arsenic trioxidetretinoinidarubicinmitoxantronemercaptopurine
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on 2006-006188-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006188-22.